CISEN(SH:603367) Zheng Quan Zhi Xing·2025-08-31 10:20Core Viewpoint - The announcement details a change in shareholding for Chenxin Pharmaceutical Co., Ltd, specifically a reduction in the stake held by major shareholders, which may impact the company's market perception and investor confidence [1][2]. Group 1: Shareholding Changes - Major shareholder Han Yanzhen and his concerted party, Nanjing Chenxin Tongtai Venture Investment Co., Ltd, have reduced their combined shareholding from 7.36% to 6.37% [1]. - The number of shares held by Han Yanzhen and Nanjing Chenxin Tongtai has decreased from 33,346,115 shares to 28,836,915 shares [1][2]. - The reduction in shareholding does not trigger mandatory tender offer obligations [1]. Group 2: Compliance and Disclosure - The company confirms that the information provided is true, accurate, and complete, with no misleading statements or significant omissions [1]. - The board of directors assures that the announcement aligns with the obligations of information disclosure [1]. - The company has previously disclosed a share reduction plan on August 6, 2025, which is referenced in this announcement [2].